Abstract CT209: Safety, efficacy and immunogenicity of VB10.16, a therapeutic DNA vaccine targeting human papillomavirus (HPV) 16 E6 and E7 proteins for high grade cervical intraepithelial neoplasia (CIN 2/3): 6-month data from an exploratory open-label phase I/2a trial

Authors: Peter Hillemanns, Karl Ulrich Petry, Linn Woelber, Gerd Böhmer, Elisabeth Stubsrud, Irene Skjørestad, Karoline Schjetne, Agnete Fredriksen, Mads Axelsen

Published: 2019-08-07

DOI: 10.1158/1538-7445.am2019-ct209

Source: Full article